Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases
- PMID: 33302545
- PMCID: PMC7764580
- DOI: 10.3390/ijms21249357
Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases
Abstract
The development of new therapeutic approaches to diseases relies on the identification of key molecular targets involved in amplifying disease processes. One such molecule is thioredoxin-interacting protein (TXNIP), also designated thioredoxin-binding protein-2 (TBP-2), a member of the α-arrestin family of proteins and a central regulator of glucose and lipid metabolism, involved in diabetes-associated vascular endothelial dysfunction and inflammation. TXNIP sequesters reduced thioredoxin (TRX), inhibiting its function, resulting in increased oxidative stress. Many different cellular stress factors regulate TXNIP expression, including high glucose, endoplasmic reticulum stress, free radicals, hypoxia, nitric oxide, insulin, and adenosine-containing molecules. TXNIP is also directly involved in inflammatory activation through its interaction with the nucleotide-binding domain, leucine-rich-containing family, and pyrin domain-containing-3 (NLRP3) inflammasome complex. Neurodegenerative diseases such as Alzheimer's disease have significant pathologies associated with increased oxidative stress, inflammation, and vascular dysfunctions. In addition, as dysfunctions in glucose and cellular metabolism have been associated with such brain diseases, a role for TXNIP in neurodegeneration has actively been investigated. In this review, we will focus on the current state of the understanding of possible normal and pathological functions of TXNIP in the central nervous system from studies of in vitro neural cells and the brains of humans and experimental animals with reference to other studies. As TXNIP can be expressed by neurons, microglia, astrocytes, and endothelial cells, a complex pattern of regulation and function in the brain is suggested. We will examine data suggesting TXNIP as a therapeutic target for neurodegenerative diseases where further research is needed.
Keywords: Alzheimer’s disease; glucose metabolism; inflammation; neuropathology; oxidative stress.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Dl-3-n-Butylphthalide Inhibits NLRP3 Inflammasome and Mitigates Alzheimer's-Like Pathology via Nrf2-TXNIP-TrX Axis.Antioxid Redox Signal. 2019 Apr 10;30(11):1411-1431. doi: 10.1089/ars.2017.7440. Epub 2018 Apr 25. Antioxid Redox Signal. 2019. PMID: 29634349
-
Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication.Mol Neurobiol. 2018 Oct;55(10):7900-7920. doi: 10.1007/s12035-018-0917-z. Epub 2018 Feb 27. Mol Neurobiol. 2018. PMID: 29488135 Free PMC article. Review.
-
ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease.Neurochem Int. 2021 Sep;148:105104. doi: 10.1016/j.neuint.2021.105104. Epub 2021 Jun 18. Neurochem Int. 2021. PMID: 34153352 Free PMC article.
-
Thioredoxin-Interacting Protein (TXNIP) Associated NLRP3 Inflammasome Activation in Human Alzheimer's Disease Brain.J Alzheimers Dis. 2019;68(1):255-265. doi: 10.3233/JAD-180814. J Alzheimers Dis. 2019. PMID: 30741672 Free PMC article.
-
Metabolic Syndrome, Brain Insulin Resistance, and Alzheimer's Disease: Thioredoxin Interacting Protein (TXNIP) and Inflammasome as Core Amplifiers.J Alzheimers Dis. 2018;66(3):857-885. doi: 10.3233/JAD-180735. J Alzheimers Dis. 2018. PMID: 30372683 Review.
Cited by
-
Oxidative Stress and Epigenetics: miRNA Involvement in Rare Autoimmune Diseases.Antioxidants (Basel). 2023 Mar 25;12(4):800. doi: 10.3390/antiox12040800. Antioxidants (Basel). 2023. PMID: 37107175 Free PMC article. Review.
-
UBQLN2 restrains the domesticated retrotransposon PEG10 to maintain neuronal health in ALS.Elife. 2023 Mar 23;12:e79452. doi: 10.7554/eLife.79452. Elife. 2023. PMID: 36951542 Free PMC article.
-
Role of Pyroptosis in Endometrial Cancer and Its Therapeutic Regulation.J Inflamm Res. 2024 Oct 3;17:7037-7056. doi: 10.2147/JIR.S486878. eCollection 2024. J Inflamm Res. 2024. PMID: 39377044 Free PMC article. Review.
-
Thioredoxin-interacting protein: A new therapeutic target in bone metabolism disorders?Front Immunol. 2022 Aug 17;13:955128. doi: 10.3389/fimmu.2022.955128. eCollection 2022. Front Immunol. 2022. PMID: 36059548 Free PMC article. Review.
-
Interleukin-35 attenuates blood-brain barrier dysfunction caused by cerebral ischemia-reperfusion injury through inhibiting brain endothelial cell injury.Ann Transl Med. 2022 Jul;10(14):776. doi: 10.21037/atm-22-2770. Ann Transl Med. 2022. PMID: 35965799 Free PMC article.
References
-
- López-Contreras A.K., Martínez-Ruiz M.G., Olvera-Montaño C., Robles-Rivera R.R., Arévalo-Simental D.E., Castellanos-González J.A., Hernández-Chávez A., Huerta-Olvera S.G., Cardona-Muñoz E.G., Rodríguez-Carrizalez A.D. Importance of the Use of Oxidative Stress Biomarkers and Inflammatory Profile in Aqueous and Vitreous Humor in Diabetic Retinopathy. Antioxidants. 2020;9:891. doi: 10.3390/antiox9090891. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials